NCT01120249

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,545 (actual)
• Sponsor: SWOG Cancer Research Network · Network
• Sex: All
• Age: 18 Years – 120 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. PURPOSE: This phase III trial is studying everolimus to see how well it works in treating patients with kidney cancer who have undergone surgery.

Detailed description

OBJECTIVES: Primary * to compare recurrence-free survival in renal carcinoma patients randomly assigned to 54 weeks of everolimus versus 54 weeks of placebo after nephrectomy or partial nephrectomy. Secondary * To compare the overall survival of patients treated with everolimus vs placebo. * To compare qualitative and quantitative toxicity between the two study arms. * To bank tissue and biologic specimens for future study of molecular biomarkers relevant to the AKT/mTOR and other pathways implicated in the pathogenesis of renal carcinoma and to investigate their potential predictive and prognostic value. * To bank blood specimens for the future study of the relationship between steady-state trough levels of everolimus and relevant side effects (lymphopenia, infection, hyperglycemia, hypercholesterolemia, hypertriglyceridemia) in patients treated on this study with everolimus. OUTLINE: This is a multicenter study. Patients are stratified according to pathologic stage (intermediate high-risk vs very high-risk), histologic subtype (clear cell vs non-clear cell), and performance status (0 vs 1). Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive oral everolimus once daily on days 1-42. Treatment repeats every 6 weeks for 9 courses in the absence of disease progression or unacceptable toxicity. * Arm II: Patients receive oral placebo once daily on days 1-42. Treatment repeats every 6 weeks for 9 courses in the absence of disease progression or unacceptable toxicity. Archived tumor tissue, plasma, and whole blood samples may be collected periodically for biomarker analysis and other translational studies. After completion of study treatment, patients are followed up every 6 months for 2 years and then annually for 8 years.

Conditions

• Kidney Cancer

Interventions

Type	Name	Description
DRUG	everolimus	Given orally
OTHER	placebo	Given orally

Timeline

• Start date: 2011-04-01
• Primary completion: 2023-07-01
• Completion: 2025-09-01
• First posted: 2010-05-10
• Last updated: 2025-09-16
• Results posted: 2024-03-20

Locations

1,003 sites across 2 countries: United States, Puerto Rico